Savara
Yahoo Finance • last year
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
LANGHORNE, Pa., July 13, 2023--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten offering of 21,000,000 shares of it... Full story
Yahoo Finance • last year
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Target Enrollment was 160 Patients, IMPALA-2 Enrolled 164 Patients Company Remains On-Track to Report Top Line Data by End of 2Q 2024 AUSTIN, Texas, June 26, 2023--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmace... Full story
Yahoo Finance • 2 years ago
Savara Announces Resignation of Chief Medical Officer
AUSTIN, Texas, August 26, 2022--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Badrul Chowdhury, M.D., Ph.D., has resigned from his role as... Full story
Yahoo Finance • 2 years ago
Savara Reports Second Quarter 2022 Financial Results and Provides Business Update
Pivotal Phase 3 IMPALA-2 Trial of Novel Inhaled Biologic, Molgramostim Nebulizer Solution (Molgramostim), in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Remains On-Track IMPALA-2 Top Line Data Expected at the End of 2Q 2024 Company... Full story
